Physician profile
Daniel Roth
NPI 1538132352
$61,138.74
in general payments reported to CMS, 2019-2025
14 companies · $24K in 2025
The $24K reported for 2025 was more than what 95% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.15 · 2021: $6,537 · 2022: $299 · 2023: $2,043 · 2024: $28K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $13K · Food and Beverage: $2,360 · Travel and Lodging: $1,997 · Honoraria: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,700.00 |
| Consulting Fee | $12,780.00 |
| Food and Beverage | $2,359.62 |
| Travel and Lodging | $1,996.62 |
| Honoraria | $1,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48,123.25 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $5,915.66 | 2021-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $4,012.13 | 2022-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $2,050.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $399.16 | 2021-2025 | Eylea Hd, Eylea |
| Eyepoint US, INC. | $285.00 | 2022-2024 | |
| Abbvie INC. | $111.52 | 2022-2025 | Ozurdex |
| Genentech USA, INC. | $110.84 | 2019-2024 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $89.87 | 2023 | Eylea |
| Bausch & Lomb Americas INC. | $27.14 | 2023 | Xipere |
| Sandoz INC. | $14.17 | 2024 | Cimerli |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.